Editorial Commentary: Tranexamic Acid for Shoulder Arthroscopy Shows Low Cost, Low Risk, Small Benefits, and Meaningful Potential to Reduce Postoperative Hemarthrosis and Operative Time.

Abstract

Tranexamic acid (TXA) has emerged as a promising adjunct in arthroscopic shoulder surgery owing to its ability to reduce bleeding and improve visualization, but its overall clinical impact appears modest. TXA likely results in a slight improvement in visual clarity, with little to no effect on postoperative pain, operative time, or blood loss. Although these findings raise questions about the role of TXA in routine shoulder arthroscopy, it may still offer benefit in specific scenarios, such as procedures with high bleeding risk or when intraoperative visualization is particularly challenging. Additionally, TXA's favorable safety profile and low cost make even small benefits worth consideration. The potential to reduce postoperative hemarthrosis or shorten operating room time in select patients could prove meaningful in terms of reducing complications and overall costs. Further investigation is warranted to determine which patient populations may benefit most.